medigraphic.com
Colegio de Medicina Interna de México.

2011, Number 5

<< Back Next >>

Med Int Mex 2011; 27 (5)

Tonsillar and rectal infiltration as the initial manifestation in AML M5

Bourlon CRA, Candelaria HMG, Violante VJA, Pérez PI, Reyes-Cordero GC, Salcido PPA

Language: Spanish
References: 14
Page: 496-501
PDF size: 534.42 Kb.


ABSTRACT

Acute myeloid leukemia belongs to an heterogeneous group of diseases as a result of rapid growth of clonal malignant hematopoietic stem cells (blasts) that produce excessive proliferation of abnormal leukemic cells. In the morphologic classification (FAB, 1976), M5 is monocytic leukemia, with an incidence of 10% in all acute myeloid leukemias. The average age of onset is about 70 years. Clinically the typical manifestations start in a few weeks with fatigue, fever and bruising or bleeding. Some organs are affected more often than others because hiperleukocytosis like lungs and the brain. We present a case report of male 42 years old who during 3 weeks developed acute myeloid leukemia monocytic subtype (M5). Atypically debuts with pharyngeal and rectal pain, secondary to infiltration. Despite of the therapeutic protocol with chemotherapy, the important affection of leukostasis and hematological alterations result in disseminated intravascular coagulation, intracerebral hemorrhage and brain death.


REFERENCES

  1. Elihu Estey, Hartmut Döhner. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.

  2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620.

  3. Kenneth D, McClatchey H. Clinical laboratory medicine. 2a ed. New York: Lippincott Williams & Wilkins, 2002;906.

  4. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukemia. Best Pract Res Clin Haematol 2001;14:19.

  5. Moorman AV, Roman E, Cartwright RA, et al. Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups. Br J Cancer 2002;86(1):60-62.

  6. Downing JR. The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev 2003;13(1):48-54.

  7. Seymour JF, Pierce SA, Kantarjian H, et al. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994;8:8234.

  8. Appelbaum FR. Acute myeloid leukemia in adults. Clinical Oncology. 3a ed. Philadelphia: Elsevier, 2004;2825-2848.

  9. Novotny JR, Muller-Beissenhirtz H, Herget-Rosenthal, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol 2005;74:501-510.

  10. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997;337:1870-1875.

  11. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;3:179-198.

  12. Uchiumi H, Matsushima T, Yamane A, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol 2007;86(2):137-142.

  13. Tallman MS, Gilliland DG, Rowe JM. Drug therapy of acute myeloid leukemia. Blood 2005;106:1154-1163.

  14. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37(6):649-658.




2020     |     www.medigraphic.com